CaaMTech
Preclinical1 active candidate
shared compound: Psilocybinsame indication: Major Depressive Disorder (MDD)Preclinical peersame regulator: US FDA
Back to StakeholdersProgramme tracker View landscape
Lead program: Preclinical
Categories
1 domain / 2 areas / 1 specialization
Red Light HollandCSE: TRIP
Data updated
1 Drug Candidate
Canadian company producing and distributing legal psilocybin magic truffles to adult consumers in the Netherlands under the iMicrodose and Trip brands. Also developing pharmaceutical-grade psilocybin formulations through its Irvine Pharma subsidiary for clinical and research applications.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 1
- Active programmes
- 1
- Lead stage
- Preclinical
- Forecast coverage
- 1 of 1
All tracked candidates active
All tracked programmes active
Current furthest stage
1 active programme with forecast fields
Latest sourced update
Filament PEX010 Selected by UCSF for Study
May 2026 - Press release - Yahoo Finance / Red Light Holland - Natural Psilocybin R&D (Irvine Labs)
Next known catalyst
No next milestone forecast yet.
5 sources0 pipeline-linked trials0 pipeline-linked papers
Development Programmes
1Natural Psilocybin R&D (Irvine Labs)
PsilocybinPreclinical
Mental health (R&D / API supply)
Programme Tracker
Major Depressive Disorder (MDD)
Primary: US (FDA)
Pre-clinicalActive
Red Light completed the Filament Health acquisition on April 30, 2026, adding botanical psilocybin IP, GMP manufacturing, and clinical authorization assets; Irvine Labs import activity remains relevant to natural psilocybin R&D.
Milestones
Company milestone
CompletedActual: Jul 1, 2025
First psilocybin shipment received by Irvine Labs under US Controlled Substances import permit
Why it matters: DEA-authorized importation of psilocybin for R&D is a significant regulatory milestone. Enables microdosing capsule development, shelf-life validation, and clinical supply manufacturing in the US.
Company milestone
CompletedActual: Nov 1, 2025
Second larger shipment (5kg) of natural psilocybin received by Irvine Labs under 2025 DEA quota; quality issues noted — shipping/customs delays impacted product condition
Why it matters: Scale-up of DEA-authorized imports, though quality degradation during transit highlights the logistical challenges of working with Schedule I substances across international borders.
Licensing deal
In progressActual: Mar 10, 2026
Signed definitive agreement to acquire Filament Health (all-share, ~182M shares issued, RLH shareholders retain ~70%); adds GMP facility in Vancouver, 76 patents (15 families), Health Canada Level 8 Dealer's Licence, supply to 70+ clinical studies; pending Q2 2026 close
Why it matters: Transformative acquisition that would give Red Light Holland actual pharmaceutical manufacturing capability and one of the largest natural psilocybin patent portfolios globally. Filament was near-insolvent (cash below $335K), making this a distressed-asset deal. If completed, RLH transitions from a consumer truffle company to a clinical supply and R&D platform.
Watch next: Q2 2026 acquisition close; integration of Filament GMP facility; first clinical supply contracts
Recorded Events
Mar 10, 2026: Licensing deal
Nov 1, 2025: Company milestone
Jul 1, 2025: Company milestone
Evidence Links
Red Light Holland Completes Acquisition of Filament Health
Press release - Newsfile / Red Light Holland - Apr 30, 2026 - Verified
Red Light completed acquisition of Filament Health, adding GMP botanical psilocybin and clinical development infrastructure.
Red Light Holland Investors - Irvine Labs Psilocybin Import Update
company-website - Red Light Holland - Nov 1, 2025 - Verified
Investor news page includes Irvine Labs receipt of a second, larger 5 kg psilocybin shipment via DEA import permit.
Filament PEX010 Selected by UCSF for Study
Press release - Yahoo Finance / Red Light Holland - May 1, 2026 - Verified
Post-acquisition update supports Filament botanical psilocybin supply activity within Red Light Holland.
Similar Developers
Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.
Usona Institute
Phase III2 active candidates23 trials
shared compound: Psilocybinsame indication: Major Depressive Disorder (MDD)same regulator: US FDAsimilar active pipeline size
BetterLife Pharma
Preclinical1 active candidate
same indication: Major Depressive Disorder (MDD)Preclinical peersame regulator: US FDAsimilar active pipeline size
Enveric Biosciences
Preclinical1 active candidate
same indication: Major Depressive Disorder (MDD)Preclinical peersame regulator: US FDAsimilar active pipeline size
Quick Facts
- Type
- Public Biotech
- Founded
- 2019
- Ticker
- CSE: TRIP
- Lead Stage
- Preclinical
- Website
- Visit